These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 12162821)

  • 1. Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain.
    Janson C; McPhee S; Bilaniuk L; Haselgrove J; Testaiuti M; Freese A; Wang DJ; Shera D; Hurh P; Rupin J; Saslow E; Goldfarb O; Goldberg M; Larijani G; Sharrar W; Liouterman L; Camp A; Kolodny E; Samulski J; Leone P
    Hum Gene Ther; 2002 Jul; 13(11):1391-412. PubMed ID: 12162821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for canavan disease.
    Matalon R; Surendran S; Rady PL; Quast MJ; Campbell GA; Matalon KM; Tyring SK; Wei J; Peden CS; Ezell EL; Muzyczka N; Mandel RJ
    Mol Ther; 2003 May; 7(5 Pt 1):580-7. PubMed ID: 12718900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global CNS gene transfer for a childhood neurogenetic enzyme deficiency: Canavan disease.
    Leone P; Janson CG; McPhee SJ; During MJ
    Curr Opin Mol Ther; 1999 Aug; 1(4):487-92. PubMed ID: 11713764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-acetylaspartate supports the energetic demands of developmental myelination via oligodendroglial aspartoacylase.
    Francis JS; Wojtas I; Markov V; Gray SJ; McCown TJ; Samulski RJ; Bilaniuk LT; Wang DJ; De Vivo DC; Janson CG; Leone P
    Neurobiol Dis; 2016 Dec; 96():323-334. PubMed ID: 27717881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aspartoacylase gene transfer to the mammalian central nervous system with therapeutic implications for Canavan disease.
    Leone P; Janson CG; Bilaniuk L; Wang Z; Sorgi F; Huang L; Matalon R; Kaul R; Zeng Z; Freese A; McPhee SW; Mee E; During MJ
    Ann Neurol; 2000 Jul; 48(1):27-38. PubMed ID: 10894213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of AAV-2-mediated aspartoacylase gene transfer in the tremor rat model of Canavan disease.
    McPhee SW; Francis J; Janson CG; Serikawa T; Hyland K; Ong EO; Raghavan SS; Freese A; Leone P
    Brain Res Mol Brain Res; 2005 Apr; 135(1-2):112-21. PubMed ID: 15857674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy.
    von Jonquieres G; Spencer ZHT; Rowlands BD; Klugmann CB; Bongers A; Harasta AE; Parley KE; Cederholm J; Teahan O; Pickford R; Delerue F; Ittner LM; Fröhlich D; McLean CA; Don AS; Schneider M; Housley GD; Rae CD; Klugmann M
    Acta Neuropathol; 2018 Jan; 135(1):95-113. PubMed ID: 29116375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system.
    Matalon R; Rady PL; Platt KA; Skinner HB; Quast MJ; Campbell GA; Matalon K; Ceci JD; Tyring SK; Nehls M; Surendran S; Wei J; Ezell EL; Szucs S
    J Gene Med; 2000; 2(3):165-75. PubMed ID: 10894262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease.
    Klugmann M; Leichtlein CB; Symes CW; Serikawa T; Young D; During MJ
    Mol Ther; 2005 May; 11(5):745-53. PubMed ID: 15851013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain Nat8l Knockdown Suppresses Spongiform Leukodystrophy in an Aspartoacylase-Deficient Canavan Disease Mouse Model.
    Bannerman P; Guo F; Chechneva O; Burns T; Zhu X; Wang Y; Kim B; Singhal NK; McDonough JA; Pleasure D
    Mol Ther; 2018 Mar; 26(3):793-800. PubMed ID: 29456021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune responses to AAV in a phase I study for Canavan disease.
    McPhee SW; Janson CG; Li C; Samulski RJ; Camp AS; Francis J; Shera D; Lioutermann L; Feely M; Freese A; Leone P
    J Gene Med; 2006 May; 8(5):577-88. PubMed ID: 16532510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel aspartoacylase (ASPA) gene mutation in Canavan disease.
    Durmaz AA; Akin H; Onay H; Vahabi A; Ozkinay F
    Fetal Pediatr Pathol; 2012 Aug; 31(4):236-9. PubMed ID: 22468686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A mutation of aspartoacylase gene in a Turkish patient with Canavan disease.
    Eke GH; Iscan A; Cece H; Calik M
    Genet Couns; 2012; 23(1):9-12. PubMed ID: 22611636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Redirecting
    Gessler DJ; Li D; Xu H; Su Q; Sanmiguel J; Tuncer S; Moore C; King J; Matalon R; Gao G
    JCI Insight; 2017 Feb; 2(3):e90807. PubMed ID: 28194442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atypical clinical and radiological course of a patient with Canavan disease.
    Sarret C; Boespflug-Tanguy O; Rodriguez D
    Metab Brain Dis; 2016 Apr; 31(2):475-9. PubMed ID: 26586007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single intravenous rAAV injection as late as P20 achieves efficacious and sustained CNS Gene therapy in Canavan mice.
    Ahmed SS; Li H; Cao C; Sikoglu EM; Denninger AR; Su Q; Eaton S; Liso Navarro AA; Xie J; Szucs S; Zhang H; Moore C; Kirschner DA; Seyfried TN; Flotte TR; Matalon R; Gao G
    Mol Ther; 2013 Dec; 21(12):2136-47. PubMed ID: 23817205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up after gene therapy for canavan disease.
    Leone P; Shera D; McPhee SW; Francis JS; Kolodny EH; Bilaniuk LT; Wang DJ; Assadi M; Goldfarb O; Goldman HW; Freese A; Young D; During MJ; Samulski RJ; Janson CG
    Sci Transl Med; 2012 Dec; 4(165):165ra163. PubMed ID: 23253610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canavan disease: studies on the knockout mouse.
    Matalon R; Michals-Matalon K; Surendran S; Tyring SK
    Adv Exp Med Biol; 2006; 576():77-93; discussion 361-3. PubMed ID: 16802706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. rAAV Gene Therapy in a Canavan's Disease Mouse Model Reveals Immune Impairments and an Extended Pathology Beyond the Central Nervous System.
    Ahmed SS; Schattgen SA; Frakes AE; Sikoglu EM; Su Q; Li J; Hampton TG; Denninger AR; Kirschner DA; Kaspar B; Matalon R; Gao G
    Mol Ther; 2016 Jun; 24(6):1030-1041. PubMed ID: 27039844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Canavan disease: a white matter disorder.
    Kumar S; Mattan NS; de Vellis J
    Ment Retard Dev Disabil Res Rev; 2006; 12(2):157-65. PubMed ID: 16807907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.